Cincinnati Children’s Hospital is investing in research of cholestatic liver diseases such as PFIC.
The NIH, FDA, and FIH have unveiled a public-private partnership aimed at accelerating gene therapies for the roughly 30 million Americans living with a rare genetic disease.
We are excited to hear that the FDA has approved Bylvay (Odevixibat) for the treatment of Progressive Familial Intrahepatic Cholestasis.
We are excited to hear that the EMA has approved Bylvay (Odevixibat) for the treatment of Progressive Familial Intrahepatic Cholestasis.
A heartfelt story about a rare and complex surgery for PFIC at HCMCT Manipal Hospitals Delhi